Overview

* Cerus ( CERS ) Q3 total revenue up 19% yr/yr, driven by 15% product revenue growth

* Adjusted EBITDA for Q3 beats analyst expectations

* Company raises full-year 2025 product revenue guidance to $202 mln - $204 mln

Outlook

* Cerus ( CERS ) raises full-year 2025 product revenue guidance to $202 mln - $204 mln, from prior outlook of $200 mln-$203 mln

* Company expects full-year 2025 IFC revenue between $16 mln and $17 mln

Result Drivers

* IFC DEMAND - Increased U.S. hospital demand for INTERCEPT Fibrinogen Complex, supported by positive case studies from academic hospitals

* GLOBAL EXECUTION - Strong global commercial execution and growing awareness of INTERCEPT Blood System benefits drove product revenue growth

* GOVERNMENT CONTRACTS - Revenue increase from government contracts due to Phase 3 RedeS trial and pathogen reduction technology development

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$20,000

Income

Q3 Beat $5 mln $2.87

Adjusted mln (3

EBITDA Analysts

)

Q3 Gross 53.40%

Margin

Q3 Gross $28.10

Profit mln

Q3 $34.40

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Cerus Corp ( CERS ) is $5.00, about 71% above its November 5 closing price of $1.45

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)